The persistent lack of diversity in clinical trials has come to the fore as one of the most salient challenges to trial success. Now we are seeing research, policy and industry commitment combine to build unprecedented momentum for impactful change—as evidenced by the April 2022 draft guidance issued by the FDA, shortly followed by the National Academies of Sciences, Engineering and Medicine’s publication of a consensus study report, Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups.
With more than 2,000 industry CEOs joining the CEO Action for Diversity & Inclusion Pledge, diversity in clinical trials has emerged as both a business and human priority.
Being intentional about diversity is important not only because of the recent FDA guidance, but because greater diversity in clinical trials has the potential to yield long-term value, by enabling a more accurate understanding and demonstration of efficacy, safety and indication-specific patient populations—insights that can be used to optimize launch and marketing strategy.
This webinar explores approaches for incorporating diversity-centric strategies into clinical development and how tech-enabled, human-centered solutions can enable companies to take action on FDA guidelines, industry commitments and the ethical responsibility to communities for diverse and equitable clinical trials.
